Multitarget therapy of malignant cancers by the head-to-tail tandem array multiple shRNAs expression system

Cancer Gene Therapy

Volumn 16, Issue 6, 2009, Pages 516-531

  Cheng, T L ^a   Teng, C F ^a   Tsai, W H ^a,b   Yeh, C W ^a   Wu, M P ^a,b   Hsu, H C ^a   Hung, C F ^a   Chang, W T ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

Author keywords

Biological signaling pathways; Cancer therapy; Human H1 promoter; Multiple shRNAs expression system; PSUPER; RNAi

Indexed keywords

CYCLIN E; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN BCL 2; PROTEIN KINASE B; SHORT HAIRPIN RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN HEK293; CELL SURVIVAL; GENE TARGETING; HELA CELL; HUMAN; HUMAN CELL; MAMMAL CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; GENETIC VECTORS; HELA CELLS; HUMANS; MALE; MODELS, GENETIC; NEOPLASMS; PROSTATIC NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING; RNA, UNTRANSLATED; TRANSFECTION;

MAMMALIA;

EID: 66149150498     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2008.102     Document Type: Article

References (38)

1. Dykxhoorn DM, Novina CD, Sharp PA.Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol 2003; 4: 457-467.
2. Grimm D, Kay MA.Combinatorial RNAi: a winning strategy for the race against evolving targets? Mol Ther 2007; 15: 878-888.
3. Siolas D, Lerner C, Burchard J, Ge W, Linsley PS, Paddison PJ et al. Synthetic shRNAs as potent RNAi triggers. Nat Biotechnol 2005; 23: 227-231.
4. Wu MT, Wu RH, Hung CF, Cheng TL, Tsai WH, Chang WT.Simple and efficient DNA vector-based RNAi systems in mammalian cells. Biochem Biophys Res Commun 2005; 330: 53-59.
5. Hanahan D, Weinberg RA.The hallmarks of cancer. Cell 2000; 100: 57-70.
6. Nelson WG, De Marzo AM, Isaacs WB.Prostate cancer. N Engl J Med 2003; 349: 366-381.
7. Chung KH, Hart CC, Al-Bassam S, Avery A, Taylor J, Patel PD et al. Polycistronic RNA polymerase II expression vectors for RNA interference based on BIC/miR-155. Nucleic Acids Res 2006; 34: e53.
8. Greber D, Fussenegger M.Multi-gene engineering: simultaneous expression and knockdown of six genes off a single platform. Biotechnol Bioeng 2007; 96: 821-834.
9. Jazag A, Kanai F, Ijichi H, Tateishi K, Ikenoue T, Tanaka Y et al. Single small-interfering RNA expression vector for silencing multiple transforming growth factor-beta pathway components. Nucleic Acids Res 2005; 33: e131.
10. O'Grady M, Raha D, Hanson BJ, Bunting M, Han son GT. Combining RNA interference and kinase inhibitors against cell signalling components involved in cancer. BMC Cancer 2005; 5: 125.
11. Sun D, Melegari M, Sridhar S, Rogler CE, Zhu L.MultimiRNA hairpin method that improves gene knockdown efficiency and provides linked multi-gene knockdown. Biotechniques 2006; 41: 59-63.
12. Wang S, Shi Z, Liu W, Jules J, Feng X.Development and validation of vectors containing multiple siRNA expression cassettes for maximizing the efficiency of gene silencing. BMC Biotechnol 2006; 6: 50.
13. Xia XG, Zhou H, Xu Z.Multiple shRNAs expressed by an inducible pol II promoter can knock down the expression of multiple target genes. Biotechniques 2006; 41: 64-68.
14. Jiang M, Milner J.Bcl-2 constitutively suppresses p53-dependent apoptosis in colorectal cancer cells. Genes Dev 2003; 17: 832-837.
15. Carvalho A, Carmena M, Sambade C, Earnshaw WC, Wheatley SP.Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. J Cell Sci 2003; 116: 2987-2998.
16. Katome T, Obata T, Matsushima R, Masuyama N, Cantley LC, Gotoh Y et al. Use of RNA interference-mediated gene silencing and adenoviral overexpression to elucidate the roles of AKT/protein kinase B isoforms in insulin actions. J Biol Chem 2003; 278: 28312-28323.
17. Liu X, Yan S, Zhou T, Terada Y, Erikson RL.The MAP kinase pathway is required for entry into mitosis and cell survival. Oncogene 2004; 23: 763-776.
18. Filleur S, Courtin A, Ait-Si-Ali S, Guglielmi J, Merle C, Harel-Bellan A et al. SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res 2003; 63: 3919-3922.
19. Guo J, Verma UN, Gaynor RB, Frenkel EP, Becerra CR.Enhanced chemosensitivity to irinotecan by RNA interference-mediated down-regulation of the nuclear factor-kappaB p65 subunit. Clin Cancer Res 2004; 10: 3333-3341.
20. Brummelkamp TR, Bernards R, Agami R.A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296: 550-553.
21. Rokhlin OW, Bishop GA, Hostager BS, Waldschmidt TJ, Sidorenko SP, Pavloff N et al. Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res 1997; 57: 1758-1768.
22. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG.Specific proteolytic cleavage of poly(ADPribose) polymerase: an early marker of chemotherapyinduced apoptosis. Cancer Res 1993; 53: 3976-3985.
23. Simbulan-Rosenthal CM, Rosenthal DS, Iyer S, Boulares AH, Smulson ME.Transient poly(ADP-ribosyl)ation of nuclear proteins and role of poly(ADP-ribose) polymerase in the early stages of apoptosis. J Biol Chem 1998; 273: 13703-13712.
24. Hung CF, Lu KC, Cheng TL, Wu RH, Huang LY, Teng CF et al. A novel siRNA validation system for functional screening and identification of effective RNAi probes in mammalian cells. Biochem Biophys Res Commun 2006; 346: 707-720.
25. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006; 441: 537-541.
26. Singh RP, Agarwal R.Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr Relat Cancer 2006; 13: 751-778.
27. Bitko V, Musiyenko A, Shulyayeva O, Barik S.Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005; 11: 50-55.
28. Gitlin L, Karelsky S, Andino R.Short interfering RNA confers intracellular antiviral immunity in human cells. Nature 2002; 418: 430-434.
29. Li BJ, Tang Q, Cheng D, Qin C, Xie FY, Wei Q et al. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat Med 2005; 11: 944-951.
30. Novina CD, Murray MF, Dykxhoorn DM, Beresford PJ, Riess J, Lee SK et al. siRNA-directed inhibition of HIV-1 infection. Nat Med 2002; 8: 681-686.
31. Palliser D, Chowdhury D, Wang QY, Lee SJ, Bronson RT, Knipe DM et al. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 2006; 439: 89-94.
32. Boden D, Pusch O, Lee F, Tucker L, Ramratnam B.Human immunodeficiency virus type 1 escape from RNA interference. J Virol 2003; 77: 11531-11535.
33. Gitlin L, Stone JK, Andino R.Poliovirus escape from RNA interference: short interfering RNA-target recognition and implications for therapeutic approaches. J Virol 2005; 79: 1027-1035.
34. Wu HL, Huang LR, Huang CC, Lai HL, Liu CJ, Huang YT et al. RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant. Gastroenterology 2005; 128: 708-716.
35. Chang LJ, Liu X, He J.Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1. Gene Therapy 2005; 12: 1133-1144.
36. Henry SD, van der Wegen P, Metselaar HJ, Tilanus HW, Scholte BJ, van der Laan LJ.Simultaneous targeting of HCV replication and viral binding with a single lentiviral vector containing multiple RNA interference expression cassettes. Mol Ther 2006; 14: 485-493.
37. ter Brake O, Konstantinova P, Ceylan M, Berkhout B. Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol Ther 2006; 14: 883-892.
38. Wu K, Mu Y, Hu J, Lu L, Zhang X, Yang Y et al. Simultaneously inhibition of HIV and HBV replication through a dual small interfering RNA expression system. Antiviral Res 2007; 74: 142-149.